Bone Biologics raises $3M, extends runway to Q2 2027, advances NB1 study

Bone Biologics Corp

Completed $3.0M private placement with healthcare-focused institutional investor; warrants could add up to $6.0M if exercised.
Operating runway extended through Q2 2027; proceeds to fund clinical trials, patent portfolio, and working capital.
NB1 first-in-human pilot study enrollment expected to complete by year-end 2026; interim updates possible.
Validated shelf life of rhNELL-1 protein extended to 29 months, up from 24 months in December 2025.
CEO Jeff Frelick highlights progress on 2026 priorities: clinical execution, product stability, IP protection, capital visibility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.